MBXMBX Biosciences, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +26% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MBX is trading
MBX Biosciences, Inc. is +433% over the past year while the S&P 500 is +18%: 414 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +26%
vs 200-day average · a clear uptrend
- RSI (14)
- 34
RSI (14) · neutral
- Below its 52-week high
- 25%
Below its 52-week high
Details›
- Last close2026-10-09
- $53.26
- 1 monthS&P 500 +2.7%
- −13%
- 1 yearS&P 500 +18%
- +433%
- vs 50-day average$62.20
- −14%
- 52-week high
- $70.67
- 52-week low
- $13.22
- Annualised volatility
- 114%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$49K
| Year | Return |
|---|---|
| 2026 (year to date) | +69% |
| 2025 | +71% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 1 of 2 | −14% |
| Feb | 2 | 0 of 2 | −7.9% |
| Mar | 2 | 0 of 2 | −16% |
| Apr | 2 | 2 of 2 | +22% |
| May | 2 | 2 of 2 | +11% |
| Jun | 2 | 1 of 2 | +26% |
| Jul | 2 | 2 of 2 | +18% |
| Aug | 2 | 2 of 2 | +8.2% |
| Sep | 2 | 1 of 2 | +5.6% |
| Oct | 3 | 1 of 3 | +1.5% |
| Nov | 2 | 1 of 2 | +23% |
| Dec | 2 | 0 of 2 | −9.0% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry